Emistat50 ml

Emistat 50 ml is a potent, highly selective serotonin 5-HT3 receptor antagonist and one of the most clinically important antiemetic agents in modern medicine. It is indicated for the prevention and treatment of nausea and vomiting across several high-risk clinical contexts where emesis can be severe, debilitating, and difficult to control with older antiemetic agents.

Chemotherapy-Induced Nausea and Vomiting (CINV)

• Prevention of acute and delayed CINV: Emistat 50 ml is indicated for the prevention of nausea and vomiting associated with both initial and repeat courses of emetogenic cancer chemotherapy — including highly emetogenic regimens (such as those containing cisplatin) and moderately emetogenic regimens (such as those containing cyclophosphamide or anthracyclines). It is effective in both adults and paediatric patients from 6 months of age.
• Emistat 50 ml significantly reduces the incidence and severity of acute vomiting occurring within the first 24 hours of chemotherapy administration and forms a cornerstone of modern CINV prophylaxis protocols.

Radiotherapy-Induced Nausea and Vomiting (RINV)

• Prevention of RINV: Emistat 50 ml is indicated for preventing nausea and vomiting in patients receiving radiotherapy, including total body irradiation, single high-dose fractions to the abdomen, and daily fractionated radiotherapy to the abdominal region — all of which carry a high risk of serotonin-mediated emesis.

Postoperative Nausea and Vomiting (PONV)

• Prevention and treatment of PONV: Emistat 50 ml is indicated for the prevention and treatment of postoperative nausea and vomiting in adults and paediatric patients. It can be administered pre-operatively (before anaesthesia induction), intra-operatively, or post-operatively depending on the clinical setting and risk profile of the patient.

Other Clinical Uses

• Nausea and vomiting of pregnancy (hyperemesis gravidarum): Emistat 50 ml is sometimes used off-label for the management of severe pregnancy-related nausea and vomiting (morning sickness and hyperemesis gravidarum) where first-line treatments have failed, though this must be under strict medical supervision.
• Gastroenteritis-related vomiting in children: Emistat 50 ml oral solution is used in paediatric practice for managing acute vomiting associated with gastroenteritis, helping to prevent dehydration by enabling oral rehydration.

Emistat 50 ml is used purely to control nausea and vomiting and does not treat the underlying causes of these symptoms. Always use under the direction of a registered physician.

Emistat 50 ml is a selective serotonin type 3 (5-HT3) receptor antagonist and a member of the carbazolone class of antiemetic drugs. It is available in multiple formulations designed to meet different clinical needs and patient populations, including tablets, oral dispersible tablets (ODT), oral solution, oral soluble film (OSF), IM/IV injection, and rectal suppositories.

The drug acts by blocking the 5-HT3 receptor — a ligand-gated ion channel widely expressed on peripheral vagal nerve terminals in the gastrointestinal tract and centrally in the area postrema (chemoreceptor trigger zone) of the brain. This targeted mechanism distinguishes Emistat 50 ml from older, non-selective antiemetics and accounts for its superior efficacy and markedly improved tolerability profile in the treatment of chemotherapy- and radiotherapy-induced emesis.

The oral soluble film (OSF) formulation is a particularly innovative delivery system: it is applied on top of the tongue, dissolves within approximately 20 seconds, and is swallowed with saliva — with no water required. This makes it especially valuable for patients with severe nausea who are unable to swallow tablets or retain liquid formulations.

Emistat 50 ml base has the molecular formula C₁₈H₁₉N₃O, with a molecular weight of 293.3. It is the racemic form of Emistat 50 ml and is commercially presented as Emistat 50 ml Hydrochloride Dihydrate for most formulations.

Emistat 50 ml is a potent and highly selective 5-HT3 (serotonin subtype 3) receptor antagonist with no significant activity at dopamine, histamine, muscarinic, or adrenergic receptors. This selectivity is the basis of its favourable side effect profile compared to older broad-spectrum antiemetics such as metoclopramide and prochlorperazine.

Mechanism of Action

• Peripheral mechanism — blockade of vagal afferents in the gut: Chemotherapeutic agents, abdominal radiotherapy, and surgical trauma trigger the release of serotonin (5-HT) from enterochromaffin cells lining the small intestinal mucosa. This serotonin activates 5-HT3 receptors on vagal afferent nerve fibres, initiating a vomiting reflex signal that travels via the vagus nerve to the vomiting centres of the brain. Emistat 50 ml blocks these peripheral 5-HT3 receptors, interrupting the initiation of this emetic reflex at its source.
• Central mechanism — blockade in the area postrema: Activation of vagal afferents can also stimulate the release of serotonin centrally in the area postrema (the chemoreceptor trigger zone), located on the floor of the fourth ventricle of the brain, which is uniquely situated outside the blood-brain barrier. This central 5-HT release promotes emesis through a direct central mechanism. Emistat 50 ml blocks 5-HT3 receptors in this region as well, providing a second level of antiemetic protection.
• Combined peripheral and central antiemetic effect: The overall antiemetic effectiveness of Emistat 50 ml in chemotherapy- and radiotherapy-induced nausea and vomiting is therefore attributable to its dual antagonism of 5-HT3 receptors on both peripheral vagal neurons in the gut and central neurons in the area postrema. The relative contribution of each site varies depending on the emetogenic stimulus.
• Postoperative nausea and vomiting: The precise mechanism by which Emistat 50 ml prevents PONV is not fully elucidated, but it is believed to share common 5-HT3-mediated pathways with CINV. Anaesthetic agents, opioids, and surgical bowel manipulation all stimulate serotonin release that contributes to postoperative emesis.

Pharmacokinetics

• Absorption: Emistat 50 ml is rapidly absorbed after oral administration. Peak plasma concentrations are achieved within approximately 1.5 to 2 hours. Oral bioavailability is approximately 60%, due to moderate first-pass hepatic metabolism. Food does not significantly affect the rate or extent of absorption.
• Distribution: Emistat 50 ml is widely distributed throughout the body with a volume of distribution of approximately 160 litres. Plasma protein binding is approximately 70 to 76%, primarily to albumin and alpha-1-acid glycoprotein.
• Metabolism: Emistat 50 ml is extensively metabolised in the liver by cytochrome P-450 enzymes, primarily CYP3A4, CYP1A2, and CYP2D6, through hydroxylation and glucuronide or sulphate conjugation. Its metabolites are pharmacologically inactive. It does not itself induce or inhibit CYP450 enzymes, limiting the risk of metabolic drug interactions.
• Elimination: The elimination half-life is approximately 3 to 4 hours in healthy adults. Less than 5% of the absorbed dose is recovered unchanged in the urine. The remainder is excreted as metabolites in the urine and faeces.
• Special populations: In patients with severe hepatic impairment, clearance is significantly reduced and the half-life is prolonged to approximately 15 to 32 hours, necessitating dose reduction. Renal impairment does not significantly alter the pharmacokinetics.

Emistat 50 ml has a relatively favourable drug interaction profile due to its selective mechanism of action. It does not itself induce or inhibit the hepatic cytochrome P-450 (CYP450) enzyme system. However, because Emistat 50 ml is metabolised by CYP450 enzymes, drugs that alter CYP450 activity may affect its plasma concentrations and clinical efficacy.

CYP450 Enzyme Interactions

• CYP450 inducers (e.g., rifampicin, carbamazepine, phenytoin, dexamethasone): These drugs accelerate the metabolism of Emistat 50 ml, reducing its plasma half-life and potentially decreasing its antiemetic efficacy. Based on available data, no routine dose adjustment of Emistat 50 ml is formally recommended in patients receiving these agents, but clinicians should be aware of possible reduced effectiveness.
• CYP450 inhibitors (e.g., ketoconazole, erythromycin, cimetidine): These agents may reduce the hepatic clearance of Emistat 50 ml, leading to increased plasma concentrations and a potentially prolonged half-life. No formal dose adjustment is currently recommended, but monitoring for enhanced side effects (such as QT prolongation) is advisable.

Critical Contraindicated Combination

• Apomorphine: Concomitant use of Emistat 50 ml with apomorphine (a dopamine agonist used in Parkinson's disease and for rapid emesis induction) is absolutely contraindicated. Profound hypotension and loss of consciousness have been reported with this combination due to pharmacodynamic interaction.

QT-Prolonging Drugs

• Emistat 50 ml causes a dose-dependent prolongation of the QT interval on the electrocardiogram (ECG). Concurrent use with other drugs that prolong the QT interval — including class IA antiarrhythmics (e.g., quinidine, procainamide), class III antiarrhythmics (e.g., amiodarone, sotalol), antipsychotics (e.g., haloperidol, droperidol), fluoroquinolone antibiotics, azole antifungals, and macrolide antibiotics — may have additive effects on QT prolongation, increasing the risk of life-threatening ventricular arrhythmias including torsades de pointes. Use with caution and with ECG monitoring in high-risk patients.

Serotonergic Drugs

• As a serotonin receptor antagonist, Emistat 50 ml may theoretically interact with other serotonergic drugs (e.g., SSRIs, SNRIs, MAOIs, tramadol). While Emistat 50 ml's antagonist action at 5-HT3 receptors is unlikely to trigger serotonin syndrome directly, caution is warranted in patients on multiple serotonergic agents.

Tramadol

• Emistat 50 ml may reduce the analgesic effectiveness of tramadol, which partially exerts its analgesic effect through serotonergic pathways. This interaction is of clinical relevance in patients receiving both drugs concurrently for pain management in the postoperative setting.

Always inform your physician of all medications currently being taken before starting Emistat 50 ml, particularly in patients with cardiac risk factors or those receiving complex chemotherapy regimens.

Emistat 50 ml is generally well tolerated across its approved indications. Most adverse effects are mild to moderate in nature and resolve without requiring discontinuation of therapy. However, clinically important rare adverse events, including serious hypersensitivity and cardiac effects, must be recognised promptly.

Common Side Effects

• Headache: The most frequently reported adverse effect of Emistat 50 ml, occurring in a significant proportion of patients. Usually mild to moderate and managed with standard analgesics if necessary.
• Constipation: A commonly reported gastrointestinal effect, particularly during chemotherapy treatment cycles. Patients should be advised to maintain adequate hydration and dietary fibre intake. Laxative therapy may be required in some cases.
• Diarrhoea: Has been reported in some patients, though less frequently than constipation. Diarrhoea is generally mild and self-limiting.

Cardiovascular Effects

• QT interval prolongation: Emistat 50 ml causes dose-dependent prolongation of the cardiac QT interval. This effect is most pronounced at higher doses (particularly 32 mg IV, which has been withdrawn from clinical use for this reason). QT prolongation increases the risk of ventricular arrhythmias, including torsades de pointes, especially in patients with pre-existing cardiac conditions, electrolyte imbalances (hypokalaemia, hypomagnesaemia), or those concurrently receiving other QT-prolonging drugs.
• Tachycardia: Rare reports of increased heart rate have been documented, particularly following intravenous administration.
• Angina (chest pain): Rare cases of chest pain have been reported; the causal relationship to Emistat 50 ml is unclear in most cases.

Hepatic Effects

• Liver enzyme abnormalities: Transient elevation of serum transaminases (ALT, AST) has been reported. In most cases, these normalise without intervention upon completion of treatment. Monitoring of liver function tests may be advisable in patients on prolonged therapy or with pre-existing liver disease.

Dermatological Effects

• Skin rash: Rash occurs in approximately 1% of patients receiving Emistat 50 ml for CINV. Usually mild and does not require treatment discontinuation.
• Flushing and sensation of warmth: Transient flushing or a feeling of warmth has been reported, particularly with IV administration.

Respiratory Effects

• Hiccups: An uncommon but notable side effect reported in some patients.
• Shortness of breath and bronchospasm: Rare cases have been reported, primarily in the context of hypersensitivity reactions.

Electrolyte Effects

• Hypokalaemia: Low potassium levels have been reported in rare cases, which may compound the risk of QT prolongation. Electrolytes should be monitored in patients at risk.

Hypersensitivity and Anaphylaxis (Rare but Serious)

• Anaphylaxis: Rare but potentially life-threatening anaphylactic reactions — including urticaria, angioedema, bronchospasm, hypotension, and cardiovascular collapse — have been reported. Immediate emergency treatment is required. Cross-reactivity with other 5-HT3 antagonists has been documented.

Neurological Effects (Rare)

• Extrapyramidal reactions: Unlike older antiemetics such as metoclopramide, Emistat 50 ml does not act on dopamine receptors and extrapyramidal effects are generally absent. However, rare isolated cases of oculogyric crisis (involuntary upward deviation of the eyes) and other dystonic reactions have been reported without definitive clinical evidence of a causal link.
• Dizziness and drowsiness: Mild and transient dizziness has been reported in isolated cases.

Report any signs of a serious allergic reaction (facial swelling, difficulty breathing, severe skin reaction) or cardiac symptoms (palpitations, irregular heartbeat, chest pain) to your physician immediately.

Pregnancy

Preclinical carcinogenicity studies in rats and mice over two years with oral Emistat 50 ml doses did not reveal any carcinogenic potential. Standard mutagenicity testing has confirmed that Emistat 50 ml is not mutagenic. Oral administration of Emistat 50 ml at doses up to 15 mg/kg per day in animal studies did not affect fertility or general reproductive performance in either male or female rats.

Reproductive toxicity studies in pregnant rats and rabbits at daily oral doses up to 15 mg/kg and 30 mg/kg per day respectively revealed no evidence of impaired fertility or foetal harm attributable to Emistat 50 ml. However, adequate and well-controlled clinical studies in pregnant women are currently lacking.

Due to the absence of sufficient human data and the potential for serious consequences in the event of harm, Emistat 50 ml should be used during pregnancy only when clearly necessary and when the potential benefit to the mother justifies any potential risk to the foetus. The decision to use Emistat 50 ml in a pregnant patient — particularly in the first trimester when organogenesis is occurring — should be made carefully and only under direct medical supervision.

Some epidemiological studies have raised concerns about a potential association between first-trimester Emistat 50 ml exposure and a small increased risk of certain cardiac malformations in the newborn, though this association remains debated in the literature. Women who are pregnant or planning pregnancy should discuss all antiemetic options with their physician to make an informed decision.

Lactation (Breastfeeding)

Emistat 50 ml is known to be excreted in the breast milk of lactating rats. Whether it is excreted into human breast milk to a clinically meaningful extent has not been definitively established.

Caution should be exercised when Emistat 50 ml is administered to a breastfeeding woman. If Emistat 50 ml is considered clinically necessary during lactation, a physician should be consulted to assess the risk-benefit balance. Temporary suspension of breastfeeding during and shortly after Emistat 50 ml administration may be considered if exposure of the infant to the drug is a concern.

The following precautions and clinical warnings must be carefully observed to ensure the safe use of Emistat 50 ml across all formulations and indications:

• Hypersensitivity and cross-reactivity: Hypersensitivity reactions — including severe anaphylaxis — have been reported in patients receiving Emistat 50 ml, including those who have previously exhibited hypersensitivity to other selective 5-HT3 receptor antagonists such as granisetron, dolasetron, or palonosetron. Cross-reactive hypersensitivity between members of this drug class has been documented. If a patient has a known allergy to any 5-HT3 antagonist, Emistat 50 ml should be used with extreme caution or avoided entirely.
• QT prolongation and cardiac arrhythmias: Emistat 50 ml prolongs the QT interval in a dose-dependent manner. The 32 mg single IV dose has been withdrawn from clinical practice worldwide due to unacceptable cardiac risk. ECG monitoring should be performed in patients with cardiac risk factors including electrolyte abnormalities (particularly hypokalaemia and hypomagnesaemia), congestive heart failure, bradycardia, or those receiving other QT-prolonging medications. Correct electrolyte imbalances before administering Emistat 50 ml wherever possible.
• Not a prokinetic agent: Emistat 50 ml does not stimulate gastric or intestinal peristalsis. It should not be used as a substitute for nasogastric suction in cases of gastric stasis or ileus. Its antiemetic action may mask symptoms of a developing intestinal obstruction or progressive ileus, particularly in patients post-abdominal surgery or receiving chemotherapy.
• Risk of masking bowel obstruction: The use of Emistat 50 ml in patients following abdominal surgery or in those with chemotherapy-induced nausea and vomiting may mask clinical signs of a progressive ileus and/or gastric distension. If a patient fails to improve clinically or develops abdominal distension, bowel obstruction must be actively excluded.
• Hepatic impairment: In patients with severe hepatic impairment (Child-Pugh Class C), clearance of Emistat 50 ml is markedly reduced and its half-life is significantly prolonged. The maximum daily dose in these patients should be limited to 8 mg administered as a single infusion over 15 minutes before chemotherapy. No further doses should be given on that day without specialist medical assessment.
• Serotonin syndrome: Although Emistat 50 ml is a 5-HT3 antagonist rather than an agonist, caution is advised when it is used with other serotonergic drugs due to the theoretical complexity of serotonin system interactions.
• Phenylketonuria (PKU): Some formulations of Emistat 50 ml (particularly orally dispersible tablets) may contain phenylalanine as a component of artificial sweeteners. Patients with phenylketonuria must be warned and appropriate formulations selected.
• Paediatric use in very young children: Limited safety and dosing information is available for paediatric patients aged 4 years or younger. Use in this age group should be under specialist supervision.

There is limited published data on deliberate or accidental Emistat 50 ml overdose in humans. The drug has a relatively wide therapeutic margin at standard clinical doses, but significant overdose can result in exaggerated pharmacological effects and serious cardiac complications, particularly QT prolongation.

Reported and Expected Symptoms of Overdose

• Visual disturbances: Transient visual disturbances, including blurred vision, have been reported.
• Severe constipation: Marked reduction in gastrointestinal motility may occur with overdose.
• Hypotension: A significant fall in blood pressure may develop, requiring supportive management.
• Vasovagal episode: Brief loss of consciousness accompanied by bradycardia has been reported following overdose in at least one case.
• QT prolongation and cardiac arrhythmia: The most clinically serious consequence of Emistat 50 ml overdose is marked QT interval prolongation, which may progress to ventricular tachycardia, torsades de pointes, or ventricular fibrillation. Continuous ECG monitoring is essential in any suspected overdose.
• Neuromuscular effects: Rare episodes of transient 2nd-degree AV block have been reported at high doses.

Management of Overdose

• There is no specific antidote for Emistat 50 ml overdose. Treatment is entirely symptomatic and supportive.
• Cardiac monitoring: Continuous ECG monitoring is mandatory to detect QT prolongation or arrhythmias early.
• Electrolyte correction: Hypokalaemia and hypomagnesaemia must be identified and corrected promptly, as these exacerbate QT prolongation.
• General supportive care: Airway management, haemodynamic support (IV fluids, vasopressors if required), and maintenance of vital functions should be instituted as clinically indicated.
• Do not attempt to self-treat an overdose. Contact the nearest emergency department or poison control centre immediately. Bring the medication packaging to aid in clinical assessment.

• Temperature: Store at a temperature not exceeding 30°C. Do not refrigerate or freeze unless specifically instructed on the product labelling (particularly for oral solution formulations).
• Dry place: Store in a cool, dry location away from areas of high humidity, such as bathrooms, laundry rooms, or kitchens. Moisture can compromise the integrity of tablets, oral soluble films, and solution formulations.
• Protect from light: Keep all Emistat 50 ml formulations in their original packaging or opaque, light-resistant containers. Direct sunlight and fluorescent lighting can accelerate the photodegradation of the active ingredient, particularly in solution and ampoule formulations.
• Protect from moisture: Tablets, ODT tablets, and oral soluble films are particularly vulnerable to moisture absorption. Keep in tightly sealed blister packs or original bottles. Do not remove oral soluble film pouches until immediately before use.
• Injection ampoules: Emistat 50 ml injection ampoules must be stored away from direct light. Once opened, the ampoule contents must be used immediately. Any unused portion of an opened ampoule must be discarded and must not be stored for later use.
• Oral solution after opening: Store opened oral solution bottles according to the instructions on the product label, typically at room temperature and away from light. Use within the period specified on the packaging after opening.
• Oral soluble film pouches: Keep each film in its individual sealed foil pouch until immediately before use. Once removed from the pouch, the film must be used immediately and must not be stored.
• Keep out of reach of children: All formulations of Emistat 50 ml — including tablets, injection ampoules, oral solution, oral soluble film, and suppositories — must be stored securely and completely out of the sight and reach of children.
• Check expiry date: Always verify the expiry date on all packaging before use. Discard expired medications through an appropriate pharmaceutical waste disposal programme.

Renal Impairment

No specific dose adjustment is required for patients with impaired renal function. The pharmacokinetics of Emistat 50 ml are not significantly affected by renal insufficiency, and the standard dosing recommendations for the general population apply across all degrees of renal impairment, including patients on haemodialysis.

Hepatic Impairment

In patients with severe hepatic impairment (Child-Pugh Class C), hepatic clearance of Emistat 50 ml is significantly reduced and the plasma half-life is markedly prolonged (up to 15 to 32 hours compared to 3 to 4 hours in healthy individuals). In this population, the maximum recommended dose is a single 8 mg dose infused intravenously over 15 minutes, administered 30 minutes before the start of emetogenic chemotherapy. No additional doses of Emistat 50 ml should be administered on the same day without specialist review. Patients with mild to moderate hepatic impairment do not generally require dose adjustment.

Paediatric Use

• 6 months to 18 years (CINV): Emistat 50 ml is approved for use in paediatric patients aged 6 months and above for the prevention of CINV, using a weight-based dosing regimen of 0.15 mg/kg per dose (up to 16 mg per dose), administered as three doses before and after chemotherapy.
• 4 to 11 years (CINV — oral solution or soluble film): Age-appropriate oral dosing regimens are available and well established for this age group.
• Children 4 years and under: Limited pharmacokinetic and clinical safety data are available for children aged 4 years or younger. Use in this age group should be approached with caution and only under specialist paediatric oncology or anaesthesia supervision.
• Paediatric PONV: Weight-based IV dosing is approved for paediatric patients undergoing surgery: 4 mg for children over 40 kg and 0.1 mg/kg for children weighing 40 kg or less.

Geriatric Use (Over 65 Years)

No specific dose adjustment is required for elderly patients (over 65 years of age). The pharmacokinetics, tolerability, and efficacy of Emistat 50 ml are generally comparable between elderly and younger adult patients. However, older adults may be more susceptible to QT prolongation due to age-related cardiovascular changes, polypharmacy, and electrolyte imbalances. Cardiac monitoring and electrolyte correction are advisable in elderly patients receiving Emistat 50 ml, particularly via the intravenous route.